News and Updates

Breakthrough T1D is focused on developing drugs, or disease-modifying therapies (DMTs), that change the course of T1D for everyone affected by it—and those yet to be. That means slowing or halting the progression of the disease, preventing it from ever occurring, and reversing it entirely through immune therapies and beta cell therapies.  Note: To enlarge the image below, left click […]

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

This article was written by Alecia Wesner (pictured above, right), a Participant Advisory Council (PAC) member, a Clinical Trial Education Volunteer, and long-time Breakthrough T1D supporter. Alecia’s story details her lived experiences with type 1 diabetes, participation in clinical trials, and her journey to joining the PAC. The views expressed by the author are her […]

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

What’s happening? Today, Bayer shared data from the phase 3 FINE-ONE clinical trial. These results, which were presented at the American Society of Nephrology Kidney Week in Houston, TX, showed that finerenone (Kerendia™/Firialta™) significantly reduces urine albumin-to-creatinine ratio (UACR), a measure of kidney damage, in people with chronic kidney disease (CKD) associated with type 1 […]

What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]

Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]

Learn about the people making the CATT1 clinical trial happen, the science behind cadisegliatin for type 1 diabetes, and how to get involved.

A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.

Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.